---
title: "Briacell 的第三阶段试验被刊登在《自然医学》杂志上"
description: "Briacell Therapeutics Corp：“将塑造 2026 年医学的十一项临床试验” – Briacell 第三阶段试验在《自然医学》上 featured"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/270160043.md"
published_at: "2025-12-18T12:45:25.000Z"
---

# Briacell 的第三阶段试验被刊登在《自然医学》杂志上

> Briacell Therapeutics Corp：“将塑造 2026 年医学的十一项临床试验” – Briacell 第三阶段试验在《自然医学》上 featured

BriaCell Therapeutics Corp：

-   “将塑造 2026 年医学的十一项临床试验” – BriaCell 第三阶段试验在《自然医学》上 featured

### Related Stocks

- [BCTX.US - BriaCell Therapeutics](https://longbridge.com/zh-CN/quote/BCTX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis \| EVMN Stock News | Evommune, Inc. announced positive results from its Phase 2a trial of EVO301 for moderate-to-severe atopic dermatitis, me | [Link](https://longbridge.com/zh-CN/news/275460224.md) |
| AbbVie Advances New Toxin-Based Therapy in Ventral Hernia Trial: What Investors Should Watch | AbbVie (ABBV) is conducting a Phase 2 clinical trial for AGN-151607-DP, a botulinum toxin-based therapy aimed at improvi | [Link](https://longbridge.com/zh-CN/news/275926867.md) |
| Tango Therapeutics CEO Teases Pivotal Vopimetostat Trial, RAS Combo Data at Guggenheim Chat | Tango Therapeutics (NASDAQ:TNGX) is advancing its PRMT5 inhibitor vopimetostat into late-stage development, as announced | [Link](https://longbridge.com/zh-CN/news/276011306.md) |
| SparingVision Successfully Completes Prodygy Trial Patient Dosing With Spvn06, Its Novel Neuroprotective Gene Therapy | SPARINGVISION SUCCESSFULLY COMPLETES PRODYGY TRIAL PATIENT DOSING WITH SPVN06, ITS NOVEL NEUROPROTECTIVE GENE THERAPYSPA | [Link](https://longbridge.com/zh-CN/news/275314326.md) |
| Eledon Pharmaceuticals Highlights BESTOW Data, Phase III Plans and FDA Timeline for “Tego” at Conference | Eledon Pharmaceuticals (NASDAQ:ELDN) executives presented data from the Phase II BESTOW kidney transplant study and outl | [Link](https://longbridge.com/zh-CN/news/275931982.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。